Phase III Study of Surovatamig Alone or With Other Cancer Medicines for Mature B-Cell Blood Cancers

What this Trial Is About

Researchers are evaluating the safety and preliminary effectiveness of surovatamig formerly AZD0486, given alone or combined with other anti-cancer drugs, for adults with mature B-cell blood cancers such as chronic lymphocytic leukemia, mantle-cell lymphoma, and large B-cell lymphoma. This open-label, multi-center study includes three substudies, each focusing on a specific type of B-cell malignancy and their treatment responses. Participants receive surovatamig through subcutaneous injection or intravenous infusion, either alone or combined with other treatments like acalabrutinib tablets or RCHOP chemotherapy rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. Different dosing schedules, including step-up dosing for priming, are used depending on the substudy and treatment combination. The study periods include a 28-day screening, a treatment period, and a follow-up phase. During the trial, participants undergo various assessments including monitoring for adverse events and dose-limiting toxicities up to six years and four months. Researchers also measure treatment response rates and drug concentration levels in the blood. Follow-up visits continue after treatment to track safety and effectiveness, with the total participation lasting several years to capture long-term outcomes.

A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies